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Abstract 
Background: HTLV type I/II is a blood borne infection that can be transmitted via blood 
transfusion.  
Objective: To determine the seroprevalence of human T – lymphotropic virus among blood donors 
in Osogbo, Nigeria. 
Methods: Diagnosis of Human T. Lymphotropic virus antigen was carried out on 372 serum 
samples among blood donors who visited the blood bank/transfusion unit of Ladoke Akintola 
University of Technology Teaching Hospital and Our Lady of Fatima Catholic Hospital, Osogbo 
between January and July 2008 using Enzyme linked immunosorbent assay techniques (ELISA) as 
described by the manufacturer.  Western blotting was used to confirm the serum reactive samples 
from ELISA. 
Results: Out of 372 samples analyzed, 14 (3.6%) samples were found to be positive for HTLV-I/II 
(7 HTLV-I and 7 HTLV-II) while 358 (96.4%) samples were negative after confirmation with 
Western blotting.  The seroprevalence of HTLV-I/II among the blood donors in Osogbo, Nigeria 
was found to be 3.6%. This has major implication for the blood transfusion service in Nigeria.  
Conclusion: The study concluded that there is need for screening of blood donor for HTLV-I/II in 
order to rule out this transfusion related infection. 
 
Keywords: human T-lymphotropic virus, T-cell leukaemia, myelopathy/tropical spastic 
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UMAN T-cell lymphotropic virus 
type 1 (HTLV-I) is a known 
aetiological agent of two major 
diseases - adult T-cell leukaemia (ATL) 1 and 
HTLV-I associated myelopathy/tropical 
spastic paraparesis (HAM/TSP).  The clinical 
features associated with HAM/TSP are 
muscle weakness in the legs, hyperreflexia, 
clonus, extensor plantar responses, sensory 
disturbances, urinary incontinence, 
impotence, and low back pain 2. HTLV-II has 
been associated with lymphoma and cases of 
atypical hairy cell leukaemia but not with 
neurological disease. The wide spectrum of 
diseases associated   with these viruses 
require that  attention  needs  to  be  paid  to  
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 these agents and further work is needed to 
determine the full public health impact of 
HTLV infection in the general population.  
HTLV-I and HTLV-II are retroviruses 
members of the Oncovirinae subfamily. The 
viruses are closely related to human 
immunodeficiency viruses types I and II 
(HIV-1 and HIV-2) which belong to 
Lentivirinae. Once a cell is infected, the RNA 
genome is converted by reverse transcriptase 
to DNA and integrates into the host genome - 
a feature shares by HIV.  HTLV-I and HTLV-
II have similar genomic organization: gag, 
pro/pol, env, and pX flanked by long terminal 
repeats (LTRs) 3. The lack of genetic 
variability of HTLV-I and HTLV-II, despite 
the long period of latency and high proviral 
load, is attributed to clonal expansion of 
HTLV-harbouring cells and not to direct viral 
replication, as is the case with HIV-1 and 
HIV-2 4.  
HTLV-I infects 15 million to 20 million 
people worldwide, with endemic foci in 
southern Japan, the Caribbean, Melanesia, 
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sub-Saharan Africa, and Central and South 
America 5, 6. The seroprevalence rate ranges 
from 3 to 6% in the Caribbean islands 7 to 
about 27% in southern Japan (Mueller et al., 
1996). HTLV-II is endemic in Amerindian 
tribes throughout North and South America 
and in Pygmy tribes in Central Africa, with 
seroprevalence ranging from 3 to 33% 8, 9. 
HTLV-I/II infections are contracted through 
sexual, vertical, and parenteral transmission. 
Intravenous drug abuse and sex with 
intravenous drug users have been found to be 
the most important risk factors for HTLV-II 
transmission 10. The high risk of blood 
transfusion transmitted HTLV-I/II has 
prompted Japan, USA, several Caribbean 
countries, Canada, France, Holland, 
Denmark, Sweden, Portugal, Australia, and 
Greece 11-13. Screening programme has been 
shown to reduce risk of transfusion related 
transmission in USA 12, 14. It was in view of 
this, that this study was undertaken. Therefore 
the aim of this study was to determine the 
seroprevalence of HTLV1/2 among the blood 
donors in Osogbo, Nigeria in order to 
highlight the importance of including this in 
transfusion microbiology services in Nigeria.  
Materials and Methods 
Sample Collection and Study Site: The 
study was carried out at Department of 
Biomedical Sciences, College of Health 
Sciences, Osogbo after collection of 5 ml of 
blood from 364 prospective blood donors that 
came in to donate blood at Blood Bank of 
Ladoke Akintola University of Technology 
Teaching Hospital, Osogbo and Our Lady of 
Fatima Catholic Hospital, Osogbo 
between January and July, 2008. The 
donors were asked to fill in a standard 
questionnaire. Serum was separated from the 
blood after the blood was allowed to clot. The 
serum samples were stored at -20oC until the 
assay for presence of antibodies to HTLVI/II 
was carried out.  
Assay for Presence of HTLV1/II 
Antibodies: Antibodies to HTLV1/2 were 
assayed in serum samples in triplicates by 
using Vitronostika HTLV-I/II microelisa kit 
(Biomèrieux, France). This assay was based 
on the principle of "sandwich" ELISA in 
which the wells of the microtitre plate were 
coated with purified HTLV-I antigens, 
purified HTLV-II antigens, and a recombinant 
HTLV-I p21E antigen. The procedures for the 
assay of the presence of antibodies to HTLV-
I/II were carried out as instructed by the 
manufacturer. Briefly, 20 μl of serum was 
added to each well, after which 80 µl of 
sample diluent provided was added, after 
which the mixture was incubated at 37oC for 
1 h to allow for antigen-antibody complex 
formation. The unbound antibodies were 
washed off the well with wash buffer (3-
cyclohexil-amino-1-propane-sulphonic acid) 
thereafter; working solution of horse radish 
peroxidase labelled goat anti-human 
immunoglobulin solution was added to each 
well and incubated at 37oC for 1 h. After 
incubation, the well was washed several times 
with washing buffer before the addition of 
tetramethyl benzidine (TMB) substrate 
solution. The colour was allowed to develop 
by incubating the mixture at room 
temperature for 30 min. The reaction was 
stopped by adding 100 µl of 1 M sulphuric 
acid to each well. Plates were read within 15 
min; the reader was blanked against air and 
the absorbance of the solution in each well 
was read at 450 nm. Results were interpreted 
according to manufacturer's instructions. 
 
Western blotting: The positive and/or 
borderline samples were further tested by a 
confirmatory Western blot assay (WB; 
HTLV-I/II Blot 2.4; Diagnostic 
Biotechnology, Singapore). A sample was 
considered HTLV-I positive if it reacted to 
the two Gag proteins (p19 and p24) and both 
env-encoded glycoproteins: the HTLV-I-
specific recombinant gp46-I peptide (MTA-1) 
and the specific HTLV-I/HTLV-II 
recombinant GD21 protein. It was considered 
HTLV-II positive if it reacted to the Gag 
protein p24 and both env-encoded 
glycoproteins: the HTLV-II-specific 
recombinant gp46-II peptide (K55) and the 
GD21 protein. Plasma samples were 
considered negative when they exhibited no 
bands and indeterminate when they were 
partially reactive. 
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Data analysis:  Statistical analysis was 
carried on the data obtained using the 
statistical package within Epi-info 6 
developed at Centre for Diseases Control and 
Prevention, Atlanta, USA 15. 
Results 
Three hundred and seventy two samples were 
tested for HTLV-I/II, 14 were found to be 
reactive, and the percentage of reactive 
samples was found to be 3.8%. None of the 
female samples was found to be reactive to 
HTLV-I/II antigens (Table 1).   
 
Table1. Prevalence of HTLV-I/II among the 
male and female blood donors in Osogbo 
Sex Number +ve (%) -Ve (%) 
Male 332 14 (4.2) 318 (89.8) 
Female 40 0 (0) 40 (10.2) 
Total 372 14 (3.8) 358 (96.2) 
 
On confirmation with Western blotting 
following the manufacturer’s interpretation, 
seven of the 14 samples were found to be 
reactive with HTLV-I antigens (p19, p24, and 
MTA-1) while the remaining seven were 
found to be reactive with HTLV-II antigens 
(p24, K55, and GD21). There was no 
significant difference between the frequency 
of seropositivity between male and female 
subjects (Χ2 = 0.78; p > 0.05). 
 Among the male subjects, 14 were found to 
be reactive to HTLV-I/II antigens 
representing 4.2% of the total male subjects in 
this study. The result also showed that the 
proportion of seropositivity was high in 
frequent donors (20%, odds ratio (OR) = 
6.83) compared to blood donors who had 
donated between 1 and 3 times (2.6 – 3.5%) 
(Table 2). 
 
Table 2: Comparison of HTLV-I/II positive people with number of donations  
 
No of donations Number of 
Subjects 
Number Reactive to 
HTLV 1/2 
% HTLV 1/2 
Seropositivity. 
Odds Ratio 
1 170 6 3.5 1.00 
2 78 2 2.6 0.72 
3 114 4 3.5 0.98 
>3 10 2 20 6.83 
 
Table 3: The effect of exposure to blood on blood donors on HTLV-I/II reactivity. 
Exposure to blood Number of Subjects HTLV-I/II Reactive
Yes 52 1 (3.85%)
No 310 6 (3.87%)
Undetermined 10 0 (0%)
Number of subjects that were seropositive to 
HTLV-I/II antigen was found to be 
comparable between subjects that had been 
previously exposed themselves to blood 
products and those subjects that had not been 
exposed to blood or blood products (Table 3). 
The prevalence of HTLV-I/II infections was 
confined to two different age groups – age 
groups between 18 and 24 (5.9%) and 25 and 
31 (12.5%) with other different age groups 
showing zero prevalence (Table 4). There was 
statistical significant difference when age 
groups between 18 and 31 were compared 
with other different age groups – 32 and 
above (Χ2 =19.48, p < 0.05). Although the 
commercial donors were not represented in 
this study, this study found there were high 
proportions of reactivity to HTLV-I/II 
antigens among family (3.2%) and voluntary 
(6.7%) blood donors (Table 5). No significant 
difference was found between the frequency 
of seropositivity among family and voluntary 
donors (Χ2 test, p value > 0.05) The 
distribution of seropositivity among different 
occupations showed that the drivers recorded 
highest seroprevalence (18.2%) to HTLV-I/II 
as indicated on Table 6 with lowest recorded 
among unemployed. 
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Table 4: Age Distribution of HTLV Seropositivity among blood donors in Osogbo 
 
Age Group Number of Subjects 
Tested 
Number of Samples 
Reactive to HTLV-I/II 
% HTLV-I/II 
seropositivity 
18-24 68 4 5.88 
25-31 80 10 12.5 
32-38 140 0 0 
39-45 56 0 0 
49-52 16 0 0 
53-62 12 0 0 
 
 
Table 5: HTLV-I/II with Donor type 
 
Type of Donor Number Tested HTLV 1/2 Reactive Percentage Reactivity 
Family 312 10 3.2 
Voluntary 60 4 6.7 
Commercial 0 0 0 
 
 
Table 6: Occupation of the donor with HTLV 
 
Occupation Number of 
donor 
HTLV-I/II Reactive % Reactivity. HTLV-I/II Odds Ratio( OR) 
Driver 22 4 18.2 1.00 
Business 24 2 8.3 0.41 
Student 40 4 10 0.50 
Security 10 0 0 0.00 
Civil servant 140 2 1.4 0.07 
Unemployed 40 2 5.0 0.24 
Others 96 0 0 0.00 
  
Discussion 
HTLV-I/II prevalence has been reported from 
different countries all over the world. For 
example, USA has reported 3-5% prevalence 
16; in Japan where the HTLV-I/II has been 
shown to be endemic, the prevalence was put 
at 27% 17; while the prevalence in Central 
Africa ranges from 3 to 33% 8,  9. Study 
carried out among the commercial sex 
workers and pregnant women in south 
western Nigeria recorded seroprevalence of 
22.9% and 16.7%, respectively 18. Recent   
work   carried out in  
Dakar, Senegal showed the prevalence of 
HTLV-I/II among blood donors was put at 
0.16% 19 as opposed to study carried out in 
1986 in Nigeria that found seroprevalence to 
be 2.0% 20. In this study, the seroprevalence  
 
of HTLV-I/II was carried out in order to 
determine whether there is any need to start 
screening blood donors for these infectious 
agents – HTLV-I/II. This study was carried 
out using Vironostika HTLV-I/II developed 
by Biomerieux which the manufacturer 
claimed    to     have   100%    sensitivity and  
specificity for screening and used Western 
blotting to confirm the reactivity of the 
samples found reactive in ELISA. In low 
resource countries like Nigeria, the ELISA 
can be used for screening of blood donors and 
any reactive sample can be prevented from 
being used for blood transfusion. Also, we 
found no evidence of cross reactivity with 
HIV as all the donors that were reactive to 
HTLV-I/II antigens were found
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not to be reactive to HIV antigen. Cross 
reactivities between HTLV and HIV has been 
reported before by Olaleye et al 21. In this 
study, the prevalence of HTLV-I/II was found 
to be 3.8% among the blood donors in 
Osogbo, Nigeria. This result has contradicted 
the result obtained in a similar study carried 
out among blood donors in nearby West 
African country – Senegal, where they found 
it to be 0.16% 19 but it is in conformity with a 
study carried out in Caribbean countries 
where they found the prevalence to be 3-6% 7.  
It is very interesting to note that the 
seroprevalence of HTLV-I/II among older age 
groups (32 years and above) in this study was 
zero while the seroprevalence among younger 
age groups (age group between 18 and 31 
years) was 9.45%, statistically significantly 
higher than other age groups (p value < 0.05), 
suggesting that this infection was not endemic 
in the past in part of Nigeria and it is now in 
the community as a result of a new way of life 
among this age group. This study was unable 
to identify the risk factor that predisposes this 
particular age group to HTLV-I/II infection so 
that necessary intervention can be introduced 
to control the infection. A study carried out in 
south western of Nigeria found the prevalence 
to be between 16 and 23% among the 
sexually active individuals including 
commercial sex workers 18; it is possible to 
attribute this factor to the high prevalence of 
HTLV-I/II in this age group. 
Furthermore, previous exposure to blood or 
blood products is shown not to play any 
significant role in the transmission of the 
microbe in this study, indicating transmission 
of the infection is not transfusion related only. 
A recent study carried on commercial sex 
workers found the prevalence to be 23% 18. 
Motor vehicle driver as an occupation has 
been pinpointed as occupation associated with 
this high prevalence of HTLV-I/II infections. 
This occupation has not been associated in 
coming in contact with blood or blood 
products. The plausible explanation that could 
be given for this is the ability of this group of 
professionals (drivers) to travel from home, 
and as a result of that they derive sexual 
pleasures from prostitutes at their temporary 
destination. Alternative reason is also they are 
group of individuals that are prone to motor 
accident as a result of their daily activities. 
Some of these accidents might require them 
of taken blood as a result of severe blood loss 
due to injury, subsequently leading to the risk 
of been infected with HTLV. Seropositivity 
of 4.8% was found among blood donors that 
have donated blood 3 times or more in this 
study, considering the fact that we have no 
commercial donor in this study    (Tables 2 
and 5). 
HTLV infection has been shown to be 
transfusion related infection22. In fact, 
posttransfusion infections due to HTLV have 
been reported22-24. Many countries in the 
world where HTLV is endemic and other 
countries with low prevalence have taken 
steps to control this infection. One of such 
intervention is to screen blood donor(s) for 
evidence of acquiring HTLV in order to 
prevent transfusion related infection. A 
similar measure has been taken to arrest the 
spread of HIV through blood transfusion. 
This important intervention has been shown 
to reduce the transmission rate of HTLV in 
USA 12, 14. Studies carried out in the 1980s 
showed the presence of antibodies to HTLV 
among blood donors in Nigeria 20, 25, despite 
this data, HTLV screening is yet to be 
incorporated into screening of blood donors in 
Nigeria and many Africa countries. 
 
Since this organism can be incorporated into 
host genome in form of proviral DNA like 
HIV, it is as good as saying this is a lifetime 
infection with no hope at the moment of 
successful treatment. Hence, subjects that are 
seropositive for HTLV are reservoir of 
infection for HTLV. Screening of blood 
donors for antibodies will eliminate the use of 
blood from subjects that have acquired HTLV 
infection. HTLV-I/II infection has increased 
from 2.0% 20 to almost 4.0% in this survey – a 
modest increase, this study strongly advocates 
for screening of blood donors for HTLV 
because the level of infection is high enough 
to start including HTLV screening as part of 
blood transfusion microbiology services in all 
the blood banks laboratories.  
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Conclusion: 
The study concluded that the prevalence of 
HTLV infection is high enough to warrant the 
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